List of Excipients in API OMIDENEPAG ISOPROPYL
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing OMIDENEPAG ISOPROPYL
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Santen Incorporated | OMLONTI | omidenepag isopropyl | 65086-002 | BENZALKONIUM CHLORIDE | 2027-09-22 |
| Santen Incorporated | OMLONTI | omidenepag isopropyl | 65086-002 | CITRIC ACID MONOHYDRATE | 2027-09-22 |
| Santen Incorporated | OMLONTI | omidenepag isopropyl | 65086-002 | EDETATE DISODIUM | 2027-09-22 |
| Santen Incorporated | OMLONTI | omidenepag isopropyl | 65086-002 | GLYCERIN | 2027-09-22 |
| Santen Incorporated | OMLONTI | omidenepag isopropyl | 65086-002 | HYDROCHLORIC ACID | 2027-09-22 |
| Santen Incorporated | OMLONTI | omidenepag isopropyl | 65086-002 | POLYOXYL 35 CASTOR OIL | 2027-09-22 |
| Santen Incorporated | OMLONTI | omidenepag isopropyl | 65086-002 | SODIUM HYDROXIDE | 2027-09-22 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for OMIDENEPAG ISOPROPYL
Excipient focus: BENZALKONIUM CHLORIDE
OMIDENEPAG ISOPROPYL drug variants containing BENZALKONIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing BENZALKONIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
Excipient focus: CITRIC ACID MONOHYDRATE
OMIDENEPAG ISOPROPYL drug variants containing CITRIC ACID MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing CITRIC ACID MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE DISODIUM
OMIDENEPAG ISOPROPYL drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERIN
OMIDENEPAG ISOPROPYL drug variants containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
OMIDENEPAG ISOPROPYL drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYOXYL 35 CASTOR OIL
OMIDENEPAG ISOPROPYL drug variants containing POLYOXYL 35 CASTOR OIL
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing POLYOXYL 35 CASTOR OIL
| Company | Ingredient | NDC |
|---|---|---|
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
OMIDENEPAG ISOPROPYL drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRISODIUM CITRATE DIHYDRATE
OMIDENEPAG ISOPROPYL drug variants containing TRISODIUM CITRATE DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing TRISODIUM CITRATE DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
OMIDENEPAG ISOPROPYL drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Santen Incorporated | omidenepag isopropyl | 65086-002 |
| Ocuvex Therapeutics Inc | omidenepag isopropyl | 84826-002 |
| >Company | >Ingredient | >NDC |
OMIDENEPAG ISOPROPYL drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch